[go: up one dir, main page]

ECSP23097121A - Isolated bispecific antibody that specifically binds CD47 and PD-L1 - Google Patents

Isolated bispecific antibody that specifically binds CD47 and PD-L1

Info

Publication number
ECSP23097121A
ECSP23097121A ECSENADI202397121A ECDI202397121A ECSP23097121A EC SP23097121 A ECSP23097121 A EC SP23097121A EC SENADI202397121 A ECSENADI202397121 A EC SENADI202397121A EC DI202397121 A ECDI202397121 A EC DI202397121A EC SP23097121 A ECSP23097121 A EC SP23097121A
Authority
EC
Ecuador
Prior art keywords
bispecific antibody
specifically binds
pharmaceutical compositions
disorders mediated
isolated bispecific
Prior art date
Application number
ECSENADI202397121A
Other languages
Spanish (es)
Inventor
Aleksandr Nikolaevich Doronin
Valery Vladimirovich Solovyev
Alexey Konstantinovich Misorin
Aleksandr Andreevich Gordeev
Dmitry Valentinovich Morozov
Sergey Aleksandrovich Legotsky
Artur Khamidovich Sabirov
Tatyana Andreevna Vodopyanova
Aleksandra Dmitrievna Azarian
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021118025A external-priority patent/RU2815823C2/en
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of ECSP23097121A publication Critical patent/ECSP23097121A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al campo de la biotecnología y la medicina, en particular a un anticuerpo biespecífico que se une específicamente a CD47 y PD-L1. La invención se refiere además a un ácido nucleico que codifica dicho anticuerpo biespecífico, un vector de expresión, una célula huésped para producir dicho anticuerpo biespecífico y un método para producir dicha célula, composiciones farmacéuticas que comprenden el anticuerpo biespecífico según la invención, composiciones farmacéuticas que comprenden el anticuerpo biespecífico según la invención y otros compuestos terapéuticamente activos, métodos para tratar enfermedades o trastornos mediados por CD47 y PD-L1, uso del anticuerpo biespecífico o composiciones farmacéuticas del mismo para tratar enfermedades o trastornos mediados por CD47 y PD-L1, y el uso del anticuerpo biespecífico según la invención y otros compuestos terapéuticamente activos para tratar enfermedades o trastornos mediados por CD47 y PD-L1.The present invention relates to the field of biotechnology and medicine, in particular to a bispecific antibody that specifically binds to CD47 and PD-L1. The invention further relates to a nucleic acid encoding said bispecific antibody, an expression vector, a host cell for producing said bispecific antibody and a method for producing said cell, pharmaceutical compositions comprising the bispecific antibody according to the invention, pharmaceutical compositions comprising They comprise the bispecific antibody according to the invention and other therapeutically active compounds, methods of treating diseases or disorders mediated by CD47 and PD-L1, use of the bispecific antibody or pharmaceutical compositions thereof to treat diseases or disorders mediated by CD47 and PD-L1, and the use of the bispecific antibody according to the invention and other therapeutically active compounds to treat diseases or disorders mediated by CD47 and PD-L1.

ECSENADI202397121A 2021-06-21 2023-12-27 Isolated bispecific antibody that specifically binds CD47 and PD-L1 ECSP23097121A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021118025A RU2815823C2 (en) 2021-06-21 Isolated bispecific antibody that specifically binds to cd47 and pd-l1

Publications (1)

Publication Number Publication Date
ECSP23097121A true ECSP23097121A (en) 2024-02-29

Family

ID=84544589

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202397121A ECSP23097121A (en) 2021-06-21 2023-12-27 Isolated bispecific antibody that specifically binds CD47 and PD-L1

Country Status (13)

Country Link
EP (1) EP4359445A1 (en)
CN (1) CN117858904A (en)
AR (1) AR126185A1 (en)
BR (1) BR112023026982A2 (en)
CL (1) CL2023003854A1 (en)
CO (1) CO2023018165A2 (en)
CR (1) CR20230612A (en)
EC (1) ECSP23097121A (en)
MA (1) MA63538A1 (en)
MX (1) MX2024000266A (en)
PE (1) PE20250352A1 (en)
TW (1) TW202306998A (en)
WO (1) WO2022271053A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2622097T3 (en) * 2009-07-24 2017-07-05 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Procedure for the development of a liquid composition to be applied as a foam on the skin as well as a composition that can be applied topically
RU2665790C1 (en) * 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Monoclonal pd-l1 antibody
EA039662B1 (en) * 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Antibodies specific to cd47 and pd-l1

Also Published As

Publication number Publication date
CN117858904A (en) 2024-04-09
EP4359445A1 (en) 2024-05-01
PE20250352A1 (en) 2025-02-06
CR20230612A (en) 2024-07-29
TW202306998A (en) 2023-02-16
MA63538A1 (en) 2024-09-30
CO2023018165A2 (en) 2024-05-30
WO2022271053A1 (en) 2022-12-29
BR112023026982A2 (en) 2024-03-12
CL2023003854A1 (en) 2024-07-19
AR126185A1 (en) 2023-09-27
MX2024000266A (en) 2024-01-31

Similar Documents

Publication Publication Date Title
PE20210321A1 (en) BIESPECIFIC ANTIBODIES AGAINST DLL3-CD3
BR112019008010A2 (en) isolated monoclonal antibody or immunologically active fragment thereof, isolated bispecific monoclonal antibody, pharmaceutical composition, method for treating a disease in a human subject in need thereof, fusion protein, cd47 gene encoded immunodominant epitope, and biological molecule
CO2018005932A2 (en) Bispecific molecules that have immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EA201791961A1 (en) ANTIBODIES SPECIFIC TO CD47 AND PD-L1
PE20221580A1 (en) THERAPEUTIC ANTIBODIES AND THEIR USES
AR110101A1 (en) MEMBERS OF UNION (2)
AU2016277883A8 (en) PD-1-CD28 fusion proteins and their use in medicine
BR112015018203A2 (en) ANTI-TNF-ANTI-IL-17 BISPECIFIC ANTIBODIES
PE20170071A1 (en) ANTIBODY MOLECULES THAT BIND AND USES LAG-3
BR112012022258A2 (en) optimized monoclonal antibodies against tissue factor path inhibitor (tfpi)
CO2021014153A2 (en) Monoclonal antibody that specifically binds to gitr
PE20191786A1 (en) MONOCLONAL ANTIBODY FOR PD-L1
BR112017027702A2 (en) Vascular Endothelial Growth Factor 2 Antireceptor Antibodies (vegfr2)
AR101735A1 (en) ANTI-BDNF THERAPEUTIC ANTIBODY (NEUROTROPHIC FACTOR DERIVED FROM THE BRAIN)
MX2021005085A (en) Antibody formulation.
AR095499A1 (en) MONOCLONAL ANTIBODIES AGAINST ANTITROMBIN b
PE20210119A1 (en) ANTI-APOC3 ANTIBODIES AND METHODS OF USE OF THEM
PE20230090A1 (en) ANTIBODIES AGAINST STEM CELL FACTOR AND METHODS OF USE THEM
ECSP23097121A (en) Isolated bispecific antibody that specifically binds CD47 and PD-L1
BR112022004941A2 (en) METHODS TO TREAT AUTOIMMUNE DISEASES WITH THE USE OF INTERLEUKIN-17 (IL-17) ANTAGONISTS
AR129553A1 (en) MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT BINDS SPECIFICALLY TO BCMA, AND ITS USE THEREOF
CO2023012549A2 (en) Monoclonal antibody or antigen-binding fragment thereof that specifically binds to gd2 (gd2 ganglioside), and use thereof
BR112023022367A2 (en) ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOF
AR127635A1 (en) MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THAT SPECIFICALLY BINDS IL-4Ra, AND USE THEREOF
BR112022012010A2 (en) ANTIBODIES, ISOLATED NUCLEIC ACID, HOST CELL, PHARMACEUTICAL FORMULATION, USE OF THE ANTIBODY, METHOD OF PRODUCTION OF AN ANTIBODY, METHOD OF TREATMENT OF AN INDIVIDUAL THAT HAS CANCER, AND METHOD OF TREATMENT OF AN INDIVIDUAL THAT HAS AN INFLAMMATORY OR AUTOIMMUNE DISEASE